- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02786277
Learning Alerts for Acute Kidney Injury
Uplift Modeling to More Narrowly Target Alerts for Acute Kidney Injury
Study Overview
Detailed Description
Acute kidney injury (AKI) carries a significant, independent risk of mortality among hospitalized patients, but despite its association with poor clinical outcomes, AKI is asymptomatic and frequently overlooked by clinicians, with fewer than half of all AKI patients with documentation of the syndrome in the electronic medical record, which was associated with decreased rates of AKI clinical best practices.
Our research group recently conducted a large-scale multicenter randomized controlled trial of electronic alerts for AKI throughout the Yale New Haven Health System from 2018 to 2020 (ELAIA-1). Our study showed that, overall, alerting physicians to the presence of AKI did not demonstrate a difference in the rate of our primary outcome of progression of AKI, dialysis, or death, despite the alert leading to some process of care changes such as measurement of creatinine and urinalysis. There was, however, substantial heterogeneity among the study sites. The proliferation of alerting systems that are ineffective can lead to the phenomenon of alert fatigue, whereby providers tend to ignore alerts in a high-alert environment, and can have deleterious effects on patient care. Further, given the highly heterogenous nature of AKI, a more personalized approach to AKI alerting may be warranted.
Uplift modeling, commonly used in marketing, is a novel concept in the medical field and aims to determine phenotypic characteristics that predict a response (benefit or harm) to a given intervention. In this way, patients who are predicted to benefit most from an intervention are identified and preferentially targeted. Uplift modeling of alerting systems has the potential to both improve alert effectiveness through intelligent targeting, and reduce alert fatigue.
In this study, we will expand upon our prior AKI alert trial to determine prospectively whether the use of uplift modeling to preferentially target patients expected to benefit from an AKI alert will reduce the rates of AKI progression, dialysis and death among hospitalized patients with AKI. Inpatients at 4 teaching hospitals within the YNHH system with AKI, based on the Kidney Disease: Improving Global Outcomes (KDIGO) creatinine criteria, will be randomized to a "recommended" group (with higher scores receiving alerts and lower scores not receiving alerts as recommended) versus an "anti-recommended" group (with higher scores not receiving alerts and lower scores receiving alerts as anti-recommended). The primary outcome will be a composite of AKI progression, dialysis, or mortality within 14 days of randomization. Secondary outcomes will focus on AKI-specific process measures.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Francis P Wilson, MD MSCE
- Phone Number: 2037371704
- Email: francis.p.wilson@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale New Haven Hospital
-
Contact:
- Francis P Wilson, MD MSCE
- Email: francis.p.wilson@yale.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults ≥ 18 years
- Admitted to a participating hospital
Has AKI as defined by creatinine criteria:
- 0.3 mg/dl increase in inpatient serum creatinine over 48 hours OR
- 50% relative increase in inpatient serum creatinine over 7 days
Exclusion Criteria:
- Dialysis order prior to AKI onset
- Initial creatinine ≥ 4.0 mg/dl
- Prior admission in which patient was randomized
- Admission to hospice service or comfort measures only order
- ESKD diagnosis code
- Kidney transplant within six months
- Opted out of electronic health record research
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Recommended
Those whose uplift score represents a probability of benefit greater than 0.5 will generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will not generate an alert.
|
An alert informing the provider of the presence of acute kidney injury will be fired.
|
Experimental: Anti-recommended
Those whose uplift score represents a probability of benefit greater than 0.5 will not generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will generate an alert.
|
An alert informing the provider of the presence of acute kidney injury will be fired.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with progression to a higher stage of AKI OR Dialysis OR Death
Time Frame: Within 14 days from randomization
|
Progression of AKI is defined as the increase in KDIGO stage from the time of randomization to the present. For patients who are discharged, we will impute 14-day creatinine using the last observation carried forward method. Dialysis is defined as the receipt of hemodialysis, continuous renal replacement therapy, or peritoneal dialysis. Isolated ultrafiltration treatments will not be included. Mortality will be determined from hospital administrative records. |
Within 14 days from randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
14-day Mortality
Time Frame: Assessed from point of randomization to date of death within 14 days of randomization
|
Proportion of patients who expire from any cause
|
Assessed from point of randomization to date of death within 14 days of randomization
|
Inpatient mortality
Time Frame: Assessed from point of randomization to date of death from any cause, up to one year post-randomization
|
Proportion of patients who expire from any cause
|
Assessed from point of randomization to date of death from any cause, up to one year post-randomization
|
14-day dialysis
Time Frame: Assessed from point of randomization to date of first documented dialysis order, within 14 days of randomization
|
Proportion of patients who receive dialysis (hemodialysis, continuous renal replacement therapy, or peritoneal dialysis)
|
Assessed from point of randomization to date of first documented dialysis order, within 14 days of randomization
|
Inpatient dialysis
Time Frame: Assess from point of randomization to date of first documented dialysis order during index hospitalization, up to one year post-randomization
|
Proportion of patients who receive dialysis (hemodialysis, continuous renal replacement therapy, or peritoneal dialysis)
|
Assess from point of randomization to date of first documented dialysis order during index hospitalization, up to one year post-randomization
|
Discharge on dialysis
Time Frame: Assessed at point of discharge from index hospitalization, up to one year post-randomization
|
Assessed as active orders for dialysis at point of discharge from index hospitalization
|
Assessed at point of discharge from index hospitalization, up to one year post-randomization
|
Progression to stage 2 AKI
Time Frame: Assessed from the date of randomization to 14 days post randomization
|
Proportion of patients with a doubling of serum creatinine from the date of randomization to 14 days post randomization
|
Assessed from the date of randomization to 14 days post randomization
|
Progression to stage 3 AKI
Time Frame: Assessed from the date of randomization to 14 days post randomization
|
Proportion of patients with a tripling of serum creatinine from the date of randomization to 14 days post randomization
|
Assessed from the date of randomization to 14 days post randomization
|
Duration of AKI
Time Frame: Assessed from the date of randomization to the cessation of AKI during index hospitalization, up to one year
|
Defined as the time in hours between AKI onset and AKI cessation during index hospitalization
|
Assessed from the date of randomization to the cessation of AKI during index hospitalization, up to one year
|
30 day readmission rate
Time Frame: Assessed from discharge date of index hospitalization to 30 days post discharge date
|
Proportion of patients with readmission within 30 days of index hospitalization discharge
|
Assessed from discharge date of index hospitalization to 30 days post discharge date
|
Index hospitalization cost
Time Frame: Assessed from point of randomization to date of discharge from index hospitalization, up to one year
|
Total cost of index hospitalization
|
Assessed from point of randomization to date of discharge from index hospitalization, up to one year
|
Chart documentation of AKI
Time Frame: Assessed from date of randomization to date of discharge from index hospitalization, up to one year
|
Proportion of patients with chart documentation of AKI as assessed by post-discharge ICD-10 codes
|
Assessed from date of randomization to date of discharge from index hospitalization, up to one year
|
Proportion of AKI "Best Practices" Achieved Per Subject During Index Hospitalization
Time Frame: 24 hours from randomization to discharge, up to one year post randomization
|
Contrast administration (de novo order of IV contrast agent within 24 hours of randomization), fluid administration (within 24 hours of randomization), aminoglycoside administration (de novo order within 24 hours of randomization), NSAID administration/cessation (de novo order or cessation of order/absence of de novo order of NSAID within 24 hours of randomization), ACE inhibitor administration/cessation, urinalysis order (with or without microscopy within 24 hours of randomization), documentation of AKI (by ICD-9 and ICD-10 codes during index hospitalization), monitoring of creatinine (at least one serum creatinine measurement within 36 hours of randomization), documentation of urine output (within 24 hours of randomization), renal consult order during index hospitalization.
Each metric is binary.
Outcome is reported as a composite best practice outcome representing the proportion of best practices achieved per subject.
|
24 hours from randomization to discharge, up to one year post randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francis P Wilson, MD MSCE, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YALEAKIALERTLEARN
- 1R01DK113191-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Ain Shams UniversityRecruiting
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
Clinical Trials on Alert
-
Brigham and Women's HospitalSanofiCompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Prevention | ProphylaxisUnited States
-
Columbia UniversityEnrolling by invitationSepsis | Electronic Health Records | Clinical Decision Support SystemsUnited States
-
Columbia UniversityEnrolling by invitationSepsis | Electronic Health Records | Clinical Decision Support SystemsUnited States
-
University of California, San FranciscoCompleted
-
Imperial College LondonCompletedType1diabetesUnited Kingdom
-
Dana-Farber Cancer InstituteCompletedBreast Cancer | Gastrointestinal Cancer | Oral Cancer Directed Therapy | Oral ChemotherapyUnited States
-
Stanford UniversityCompleted
-
Cedars-Sinai Medical CenterTerminated
-
Guangdong Provincial People's HospitalUnknownAcute Kidney Injury
-
Indiana UniversityNational Institute on Aging (NIA)Not yet recruiting